The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2024 | Managing patients with multiple myeloma who have stopped treatment prior to relapse
Meral Beksac, MD, PhD, Istinye University Ankara Liv Hospital, Ankara, Turkey, discusses the timing and management of disease progression after stopping therapy in patients with multiple myeloma. She emphasizes that patients with high-risk profiles may require ongoing treatment even if they achieve measurable residual disease (MRD) negativity. In contrast, standard and very good-risk patients might not need immediate treatment, as they could enter a secondary monoclonal gammopathy of undetermined significance (MGUS) state. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
